Inhibitor of LRRK2



  • LRRK2
  • Inhibitor

In Vitro Validations

Uniprot ID: Q5S007
Target Class: Protein kinase
Target SubClass: TKL
Potency: IC50
Potency Value: 1.8 nM
Potency Assay: MSD and Invitrogen assay
PDB ID for probe-target interaction (3D structure): 5U6I
Structure-activity relationship: yes see ref. DOI: 10.1021/acs.jmedchem.7b00045
Target aliases:
Leucine-rich repeat serine/threonine-protein kinas ...

In Cell Validations

In Vivo Data

Off-Target Selectivity Assesments

Potency end-point : IC50
Potency assay (off target): KinomeScan
Probe Selectivity in Vitro:

> 100-fold kinome selective with IC50 < 1 µM for the following kinases: CLK4 (225 nM), MAP3K14 (244 nM), MAP3K5 (428 nM), CLK2 (605 nM), and TTK (935 nM).

Potency assay, off target (cells): PanLabs Profiling
Probe Selectivity in Cell:

PanLabs Profile shows 5 hits > 50% inhibition (@ 10 μM): HTR2B (1.2 µM), SLC6A2 (3.8 µM), CHRM2 (6.4 µM), PPARG (6.5 µM), adenosine transporter (9.7 µM). NanoBRET results (SGC Frankfurt): CLK4 IC50 = 971 nM, MAP3K14 IC50 = 29.7 µM, MAP3K5 IC50 > 20 µM, CLK2 IC50 = 1,.38 µM, TTK IC50 = 6.62 µM

I have extra information to add

SERP ratings and comments

SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

In a mouse model of idiopathic PD, MLi-2 was well-tolerated and showed robust target engagement. However, LRRK2 kinase inhibition in the MitoPark model did not prevent motor dysfunction, α-synuclein pathology or neuron death.

(last updated: 5 Jun 2020 )

SERP Ratings

In Cell Rating
In Model Organisms

SERP Comments:

While there are multiple commercially available LRRK inhibitors available, MLi-2 provides another quality chemical probe to help validate this target in cell-based assays.

(last updated: 3 Jul 2020 )